重庆医科大学学报2024,Vol.49Issue(5) :588-592.DOI:10.13406/j.cnki.cyxb.003485

多发性硬化疾病修正治疗进展

Advances in disease-modifying therapy for multiple sclerosis

谭红梅 全超
重庆医科大学学报2024,Vol.49Issue(5) :588-592.DOI:10.13406/j.cnki.cyxb.003485

多发性硬化疾病修正治疗进展

Advances in disease-modifying therapy for multiple sclerosis

谭红梅 1全超1
扫码查看

作者信息

  • 1. 复旦大学附属华山医院神经内科/国家神经疾病医学中心,上海 200040
  • 折叠

摘要

疾病修正治疗(disease-modifying therapy,DMT)是多发性硬化(multiple sclerosis,MS)缓解期减少复发、改善预后的标准治疗.目前多种不同作用靶点和机制的DMT药物已在国内获批上市.随着对MS疾病机制的认识不断加深,对MS治疗目标的不断提高,多种新型药物也在积极开展临床试验,以追求更佳的疗效,更好的安全性.本文将对国内已获批DMT药物的作用机制、临床试验结果进行介绍,并对几种新型DMT药物的研究现状进行综述.

Abstract

Disease-modifying therapy(DMT)is the standard therapy for reducing recurrence and improving prognosis during the remission stage of multiple sclerosis(MS).A variety of DMT drugs with different action targets and mechanisms have been approved and marketed in China.With a deeper understanding of the pathophysiology of MS and the improvement of the treatment goals for MS,clinical trials are being conducted for several novel drugs to pursue better efficacy and safety.This article introduces the mechanism of action and clinical trial results of the DMT drugs approved in China and reviews the current research status of several new DMT drugs.

关键词

多发性硬化/疾病修正治疗/无疾病活动证据

Key words

multiple sclerosis/disease-modifying therapy/no evidence of disease activity

引用本文复制引用

基金项目

国家自然科学基金(82171341)

出版年

2024
重庆医科大学学报
重庆医科大学

重庆医科大学学报

CSTPCD北大核心
影响因子:0.724
ISSN:0253-3626
参考文献量45
段落导航相关论文